Reuters -- Swiss biotech company Cytos (CYTN.S) is aiming to clinch a partnering deal worth over 600 million Swiss francs ($541 million) for its asthma vaccine after strong mid-trial data, the group’s head was quoted as saying.
Reuters -- Swiss biotech company Cytos (CYTN.S) is aiming to clinch a partnering deal worth over 600 million Swiss francs ($541 million) for its asthma vaccine after strong mid-trial data, the group’s head was quoted as saying.
